4 completed, 2 recruiting, 1 active not recruiting. 7 Phase 2, 2 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 4, Recruiting 2, Active not recruiting 1 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
| Phase 3 | 2 | Completed 1, Recruiting 1 |
Follow Placebo oral solution: new trials by email Literature Review of Placebo oral solution trials Research Report on Placebo oral solution
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CBD for Pain Following Orthopedic Shoulder Surgery Epidiolex, Placebo oral solution - Shoulder Osteoarthritis, Rotator Cuff Injuries | Phase 1 / Phase 2 | Recruiting | The Methodist Hospital Research Institute | 80 | 2024-05-24 | 2026-04-16 |
| Enhancing Prolonged Exposure With Cannabidiol to Treat Posttraumatic Stress Disorder Cannabidiol (CBD) oral solution, Placebo, Massed Prolonged Exposure (mPE) - Posttraumatic Stress Disorder, Stress Disorders, Post-Traumatic | Phase 1 / Phase 2 | Completed | The University of Texas Health Science Center at San Antonio | 21 | 2022-04-04 | 2024-10-10 |
| Efficacy of Adaptogens in Patients With Long COVID-19 ADAPT-232 oral solution, Placebo oral solution - Covid19 | Phase 2 / Phase 3 | Completed | Swedish Herbal Institute AB | 100 | 2021-04-19 | 2021-12-28 |
| A Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 in Patients With PSP AZP2006 oral solution, Placebo oral solution - Progressive Supranuclear Palsy | Phase 2 | Completed | AlzProtect SAS | 36 | 2020-06-22 | 2025-03-17 |
| Trial of Cannabidiol to Treat Severe Behavior Problems in Children With Autism Epidiolex, placebo oral solution - Autism, Autism Spectrum Disorder | Phase 2 | Active not recruiting | University of California, San Diego | 42 | 2020-06-01 | 2025-09-30 |
| Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial Memantine Hydrochloride Oral Solution, Trazodone Hydrochloride oral solution, Placebo oral solution - Motor Neuron Disease, Amyotrophic Lateral Sclerosis | Phase 2 / Phase 3 | Recruiting | University of Edinburgh | 1150 | 2020-02-27 | 2026-03-04 |
| A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults FE 201836, Desmopressin, Placebo oral solution - Nocturia | Phase 2 | Completed | Ferring Pharmaceuticals | 302 | 2017-07-27 | 2022-03-02 |
Amyotrophic Lateral Sclerosis (1) · Anxiety Disorders (1) · Autism Spectrum Disorder (1) · Autistic Disorder (1) · COVID-19 (1) · Cognition Disorders (1) · Depression (1) · Fatigue (1) · Headache (1) · Nocturia (1) · Post-Acute COVID-19 Syndrome (1) · Rotator Cuff Injuries (1) · Stress Disorders, Post-Traumatic (1) · Supranuclear Palsy, Progressive (1)
AlzProtect SAS (1) · Ferring Pharmaceuticals (1) · Swedish Herbal Institute AB (1) · The Methodist Hospital Research Institute (1) · The University of Texas Health Science Center at San Antonio (1) · University of California, San Diego (1) · University of Edinburgh (1)
United States (4) · Belgium (1) · Canada (1) · Czechia (1) · France (1) · Georgia (1) · Germany (1) · Hungary (1) · Poland (1) · United Kingdom (1)
Casey Straud, PsyD (1) · Doris Trauner, MD (1) · Irina Karosanidze, PhD, MD (1) · Patrick McCulloch, MD (1) · Philippe Verwaerde, PhD (1)
PMID 35798516, PMID 36647114, PMID 36725099, PMID 39307154, PMID 40410546
2016 (1), KL2TR002646 (1), UL1TR002645 (1)